These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31571207)

  • 1. The evolving role of next generation sequencing in myelodysplastic syndromes.
    Spaulding TP; Stockton SS; Savona MR
    Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
    Hughes CFM; Gallipoli P; Agarwal R
    Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Noy-Lotan S; Krasnov T; Dgany O; Jeison M; Yanir AD; Gilad O; Toledano H; Barzilai-Birenboim S; Yacobovich J; Izraeli S; Tamary H; Steinberg-Shemer O
    Br J Haematol; 2021 May; 193(3):570-580. PubMed ID: 33368157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
    Kawata E; Lazo-Langner A; Xenocostas A; Hsia CC; Howson-Jan K; Deotare U; Saini L; Yang P; Broadbent R; Levy M; Howlett C; Stuart A; Kerkhof J; Santos S; Lin H; Sadikovic B; Chin-Yee I
    Br J Haematol; 2021 Feb; 192(4):729-736. PubMed ID: 32588428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
    Anwar N; Memon FA; Shahid S; Shakeel M; Irfan M; Arshad A; Naz A; Ujjan ID; Shamsi T
    BMC Genomics; 2021 Dec; 22(1):903. PubMed ID: 34915860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.
    Nassereddine S; Nishihori T; Padron E; Mahfouz R; Bazarbachi A; Komrokji RS; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):7-13. PubMed ID: 27771290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
    Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
    BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of myelodysplastic syndrome in the era of next-generation sequencing.
    Tobiasson M; Kittang AO
    J Intern Med; 2019 Jul; 286(1):41-62. PubMed ID: 30869816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E;
    Br J Haematol; 2020 Mar; 188(5):605-622. PubMed ID: 31621063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Getting personal with myelodysplastic syndromes: is now the right time?
    Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
    Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
    Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.
    Lew JL; Fenderson JL; Carmichael MG
    Hawaii J Med Public Health; 2017 Nov; 76(11 Suppl 2):10-12. PubMed ID: 29164009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].
    Cheng HC; Liu SW; Liu Y; Zhao XF; Li W; Qiu L; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1631-1635. PubMed ID: 29262888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.